Australia's Argent BioPharma rises to over 1-month high on new licence agreement
29/09/2026 03:47
BUZZ-Australia's Argent BioPharma rises to over 1-month high on new licence agreement ** Shares of Argent BioPharma RGT.AX rise as much as 25% to A$0.040, their highest level since August 21
** Stock logs its largest intraday pct gain since July 31
** The biopharma company enters a licence agreement with NLC, others to commercialise the antiviral applications addressed by NLC's Tollovir and NutraVir products
** NutraVir is presented as a dietary supplement
** YTD, Argent stock down 52.9%
($1 = $1.0000)
(Reporting by Tejas Harish in Bengaluru)
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program